Axsome Therapeutics steels itself for FDA rejection of migraine drug

According to the US health authority, Axsome Therapeutics has been unable to solve a number of problems with its manufacturing conditions for migraine candidate AXS-07, and as a consequence, the US-based firm is preparing for the drug’s final rejection.

A new migraine candidate is seemingly not making it all the way to market | Photo: Andrew Kelly/Reuters/Ritzau Scanpix

An increase in Covid-19 cases delayed the US Food and Drug Administration’s (FDA) planned manufacturing site inspections of Axsome Therapeutics, which left the company waiting for answers for one of its pending candidates, as reported by industry media Fierce Biotech.

As it turns out, not all things come to those who wait, as the FDA has reportedly filed a report with the US Securities and Exchange Commission (SEC) that identifies chemistry, manufacturing and control issues in the application regarding AXS-07, a migraine treatment, concluding that problems were left “unresolved.”

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs